Hologic, Inc. (NASDAQ:HOLX) Shares Bought by Pathstone Holdings LLC

Pathstone Holdings LLC raised its position in Hologic, Inc. (NASDAQ:HOLX) by 7.7% in the 3rd quarter, Holdings Channel reports. The fund owned 29,731 shares of the medical equipment provider’s stock after acquiring an additional 2,121 shares during the period. Pathstone Holdings LLC’s holdings in Hologic were worth $2,422,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Wolff Wiese Magana LLC acquired a new stake in Hologic in the third quarter valued at about $25,000. Innealta Capital LLC purchased a new position in shares of Hologic during the 2nd quarter worth approximately $25,000. iA Global Asset Management Inc. acquired a new stake in shares of Hologic in the 1st quarter valued at approximately $37,000. Sunbelt Securities Inc. purchased a new stake in shares of Hologic in the second quarter valued at approximately $37,000. Finally, Cromwell Holdings LLC grew its holdings in Hologic by 330.2% during the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 416 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Stock Up 1.0 %

HOLX opened at $79.73 on Tuesday. The firm has a market cap of $18.52 billion, a P/E ratio of 23.94, a PEG ratio of 2.49 and a beta of 0.98. The business’s fifty day simple moving average is $80.38 and its 200 day simple moving average is $78.38. Hologic, Inc. has a 52 week low of $67.59 and a 52 week high of $84.67. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting analysts’ consensus estimates of $1.01. The business had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.89 earnings per share. As a group, equities research analysts anticipate that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Citigroup lowered shares of Hologic from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $95.00 to $85.00 in a research report on Tuesday, October 1st. Leerink Partners lowered their target price on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Raymond James lifted their price target on shares of Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price objective on shares of Hologic in a report on Tuesday, October 15th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $89.91.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.